Celgene closed the most recent trading day at $87.62, moving +1.34% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.85%. Meanwhile, the Dow gained 0.75%, and the Nasdaq, a tech-heavy index, added 1.29%.
Coming into today, shares of the biotechnology company had gained 37.65% in the past month. In that same time, the Medical sector gained 9.03%, while the S&P 500 gained 12.44%.
Investors will be hoping for strength from CELG as it approaches its next earnings release, which is expected to be January 31, 2019. The company is expected to report EPS of $2.32, up 16% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $3.98 billion, up 14.21% from the year-ago period.
Investors should also note any recent changes to analyst estimates for CELG. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 1.02% higher. CELG is holding a Zacks Rank of #1 (Strong Buy) right now.
In terms of valuation, CELG is currently trading at a Forward P/E ratio of 8.34. This represents a discount compared to its industry's average Forward P/E of 21.93.
We can also see that CELG currently has a PEG ratio of 0.41. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.46 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 53, which puts it in the top 21% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CELG in the coming trading sessions, be sure to utilize Zacks.com.
Image: Bigstock
Celgene (CELG) Outpaces Stock Market Gains: What You Should Know
Celgene closed the most recent trading day at $87.62, moving +1.34% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.85%. Meanwhile, the Dow gained 0.75%, and the Nasdaq, a tech-heavy index, added 1.29%.
Coming into today, shares of the biotechnology company had gained 37.65% in the past month. In that same time, the Medical sector gained 9.03%, while the S&P 500 gained 12.44%.
Investors will be hoping for strength from CELG as it approaches its next earnings release, which is expected to be January 31, 2019. The company is expected to report EPS of $2.32, up 16% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $3.98 billion, up 14.21% from the year-ago period.
Investors should also note any recent changes to analyst estimates for CELG. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 1.02% higher. CELG is holding a Zacks Rank of #1 (Strong Buy) right now.
In terms of valuation, CELG is currently trading at a Forward P/E ratio of 8.34. This represents a discount compared to its industry's average Forward P/E of 21.93.
We can also see that CELG currently has a PEG ratio of 0.41. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.46 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 53, which puts it in the top 21% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CELG in the coming trading sessions, be sure to utilize Zacks.com.